These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 20458086)
1. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Howell MD; Novack V; Grgurich P; Soulliard D; Novack L; Pencina M; Talmor D Arch Intern Med; 2010 May; 170(9):784-90. PubMed ID: 20458086 [TBL] [Abstract][Full Text] [Related]
2. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Aseeri M; Schroeder T; Kramer J; Zackula R Am J Gastroenterol; 2008 Sep; 103(9):2308-13. PubMed ID: 18702653 [TBL] [Abstract][Full Text] [Related]
3. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Stevens V; Dumyati G; Brown J; Wijngaarden E Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992 [TBL] [Abstract][Full Text] [Related]
9. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection. Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413 [TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. McFarland LV; Clarridge JE; Beneda HW; Raugi GJ Clin Infect Dis; 2007 Nov; 45(9):1141-51. PubMed ID: 17918075 [TBL] [Abstract][Full Text] [Related]
11. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Jayatilaka S; Shakov R; Eddi R; Bakaj G; Baddoura WJ; DeBari VA Ann Clin Lab Sci; 2007; 37(3):241-7. PubMed ID: 17709687 [TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Yearsley KA; Gilby LJ; Ramadas AV; Kubiak EM; Fone DL; Allison MC Aliment Pharmacol Ther; 2006 Aug; 24(4):613-9. PubMed ID: 16907893 [TBL] [Abstract][Full Text] [Related]
14. Acid-Suppressing Agents and Risk for Clostridium difficile Infection in Pediatric Patients. Brown KE; Knoderer CA; Nichols KR; Crumby AS Clin Pediatr (Phila); 2015 Oct; 54(11):1102-6. PubMed ID: 25644650 [TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study. Leonard AD; Ho KM; Flexman J Intern Med J; 2012 May; 42(5):591-4. PubMed ID: 22616966 [TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Barletta JF; Sclar DA Crit Care; 2014 Dec; 18(6):714. PubMed ID: 25540023 [TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. Kim YG; Graham DY; Jang BI J Clin Gastroenterol; 2012; 46(5):397-400. PubMed ID: 22298089 [TBL] [Abstract][Full Text] [Related]
18. Potential influence of antisecretory therapy on the development of Candida-associated intraabdominal infection. Cat TB; Charash W; Hebert J; Marden BT; Corbett SM; Ahern J; Rebuck JA Ann Pharmacother; 2008 Feb; 42(2):185-91. PubMed ID: 18212256 [TBL] [Abstract][Full Text] [Related]
20. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients. Ro Y; Eun CS; Kim HS; Kim JY; Byun YJ; Yoo KS; Han DS Gut Liver; 2016 Jul; 10(4):581-6. PubMed ID: 27021503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]